HIGHTIDE-B (02511): Chen Mingyu appointed as an independent non-executive director.
Kun Sheng Tai Medicine-B (02511) announced that Mr. Chen Mingyu (Mr. Chen) has been appointed as an independent non-executive director, the chairman of the company's audit committee, and a member of the company's remuneration committee, effective from May 4, 2026.
HIGHTIDE-B (02511) announcement that Mr. Chen Mingyu (Mr. Chen) has been appointed as an independent non-executive director, chairman of the Company's Audit Committee, and member of the Company's Remuneration Committee, effective from May 4, 2026.
Related Articles
CF PHARMTECH (02652) spent 123,000 Hong Kong dollars to repurchase 5,500 shares on May 4th.
On May 4th, SIMCERE PHARMA (02096) spent 10.165 million Hong Kong dollars to repurchase 847,000 shares.
On May 4th, GUOQUAN (02517) spent 1.9934 million Hong Kong dollars to repurchase 593,200 shares.
CF PHARMTECH (02652) spent 123,000 Hong Kong dollars to repurchase 5,500 shares on May 4th.
On May 4th, SIMCERE PHARMA (02096) spent 10.165 million Hong Kong dollars to repurchase 847,000 shares.
On May 4th, GUOQUAN (02517) spent 1.9934 million Hong Kong dollars to repurchase 593,200 shares.
